One-on-one: TDD Chats with UNION Therapeutic’s CO-CEO Kim Kjøller About the New RAVE Data on Orismilast in AD
Orismilast is showing promise in atopic dermatitis (AD), according to topline results from the ADESOS study presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference in Chicago, IL. This marks the first presentation of data from this study. Orismilast is a next-generation, high-potency PDE4 B/D selective inhibitor with reported positive results from […]